GNG5 and Alzheimer disease: Considering a significant reduction in GNG5 in brain-derived EVs and serum-derived EVs from patients with AD, we suggest that GNG5 is a novel regulator of Aβ42 and a potential early diagnosis biomarker and drug target for AD.